Autologous hematopoietic cell therapy (Genethon)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAutologous hematopoietic cell therapy (Genethon)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionNADPH Oxidase 2 modulators

TargetsNADPH Oxidase 2

Therapy Area/IndicationsGranulomatous Disease, Chronic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesGenethon

China Registration ClassN/A

Develop Information

Active CompaniesGenethon

Inactive CompaniesN/A

Active IndicationsGranulomatous Disease, Chronic

Inactive IndicationsN/A

Other Information

ATC CodeN/A